Loriaux D L, Wild R A
Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health Sciences University.
Am J Obstet Gynecol. 1993 Jun;168(6 Pt 2):2021-6. doi: 10.1016/s0002-9378(12)90944-8.
Previous confusion regarding the interference by oral contraceptives in measurements of endocrine function have been largely eliminated by the advent of improved, more sensitive assays. There are few if any contraindications to oral contraceptive use in patients with thyroid disease. Patients with prolactinoma can be treated with bromocriptine to restore fertility and prevent mineral loss. However, as a less expensive alternative, oral contraceptives can be prescribed to correct mineral loss, because there is no convincing evidence of an adverse effect on prolactinomas by the steroidal content of the pill. Oral contraceptives comprise a near ideal treatment modality for women with polycystic ovary disease because, among other effects, oral contraceptives reduce synthesis of androgen by inhibiting pituitary gonadotropin secretion.
随着更先进、更灵敏检测方法的出现，以往口服避孕药干扰内分泌功能测定所造成的混淆已基本消除。甲状腺疾病患者使用口服避孕药几乎没有禁忌证。泌乳素瘤患者可用溴隐亭治疗以恢复生育能力并防止骨质流失。然而，作为一种较便宜的替代方法，也可开具口服避孕药来纠正骨质流失，因为尚无确凿证据表明避孕药中的甾体成分会对泌乳素瘤产生不良影响。口服避孕药对多囊卵巢疾病女性而言几乎是一种理想的治疗方式，因为口服避孕药除了其他作用外，还可通过抑制垂体促性腺激素分泌来减少雄激素的合成。
